Design, Formulation and Evaluation of Buccal Disintegrating Tablet Containing Anticonvulsant Agent

This study focuses on the formulation and evaluation of buccal disintegrating tablets (BDTs) of Clonazepam, an anticonvulsant drug, to enhance bioavailability, ensure rapid onset of action, and improve patient compliance, especially for non-cooperative or unconscious patients. Various superdisintegrants including Crospovidone, Croscarmellose Sodium (CCS), and Sodium Starch Glycolate (SSG) were utilized in combination to develop and compare formulations. Among the prepared batches, the formulation containing a combination of Crospovidone and CCS (F4) showed the most promising results in terms of disintegration time, drug release and stability.